RedLeaf Biologics
RedLeaf Biologics produces ReDaxin, a patented red sorghum leaf extract used as a bioactive ingredient by formulators in dietary supplements, functional food and beverage, and cosmetics, via a U.S.-based, SQF-certified seed-to-extract value chain using proprietary aqueous extraction.
- Company typePrivate
- Founded2009
- HeadquartersNicholasville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RedLeaf Biologics does
RedLeaf Biologics is a private Kentucky-based ingredient company that produces and sells ReDaxin™, a patented red sorghum leaf extract marketed as a bioactive ingredient for dietary supplement, functional food and beverage, and cosmetic manufacturers. Founded in 2015 and tracing its core genetic asset to a one-in-two-million red sorghum plant discovered in a Kentucky sorghum field in 2009, the company operates a fully U.S.-based, SQF-certified seed-to-extract value chain in which it partners with domestic farmers to grow its patented non-GMO red sorghum varietal and processes the leaves in-house.
ReDaxin is the company's sole commercial product and is positioned as the first and only patented red sorghum leaf extract, a phenolic-rich botanical containing greater than 20% polyphenols, including luteolin, quercetin, hydroxycinnamic acids, and rare 3-deoxyanthocyanidins. The extract is produced via a proprietary aqueous (water-based) extraction process that yields a water-soluble, clean-label ingredient stable across a broad pH range, temperature, and light conditions, and is supplied in formats spanning capsules, tablets, ready-to-drink beverages, powders, stick packs, gummies, gels, functional foods, and cosmetic applications. Recent validation includes a 2025 University of Kentucky clinical study showing enhanced muscle strength recovery after eccentric exercise.
RedLeaf generates revenue through quote-based B2B ingredient supply agreements with formulators, with pricing not publicly disclosed. Commercial engagement is consultative, with prospects requesting samples, clinical study data, and quotes via the company website. ReDaxin is supported by a broad certification stack — self-affirmed GRAS, Non-GMO Project Verified, Kosher, Halal, Vegan, Gluten-Free, Made in America, and TruShield (received November 2025) — and is positioned for high-purity, clean-label formulation across regulated end-markets. The company has been grant-funded, including two NSF SBIR awards totaling approximately $1.53M and a 2024 Bluegrass AgTech Development Corp grant, and is led by co-founder and CEO Seth DeBolt, co-founder Heather Youngs, and co-founder Chris Somerville.
RedLeaf Biologics firmographics
Firmographics- Name
- RedLeaf Biologics
- Legal name
- RedLeaf Biologics
- Website
- https://redleafbiologics.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RedLeaf Biologics produces ReDaxin, a patented red sorghum leaf extract used as a bioactive ingredient by formulators in dietary supplements, functional food and beverage, and cosmetics, via a U.S.-based, SQF-certified seed-to-extract value chain using proprietary aqueous extraction.
- Ownership category
- akta.pro rank
RedLeaf Biologics industry classification
Industry- Product category
- Botanical Extract Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)
- akta.pro secondary industries
- Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol) (AFAJAKAI), Herbal & Botanical Supplements (CRADAGAD)
Keywords
Where RedLeaf Biologics is headquartered
LocationHeadquarters
- HQ city
- Nicholasville
- HQ country
- United States
- HQ region
- North America
Markets served
RedLeaf Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- B2B Ingredient Sales to Formulators: RedLeaf Biologics sells its patented ReDaxin™ red sorghum leaf extract as a raw bioactive ingredient to formulators and brand manufacturers in the dietary supplement, functional food & beverage, and cosmetics industries via inquiry-based B2B engagement. Revenue is generated through ingredient supply agreements (B2B sales of physical ingredient SKUs).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based B2B ingredient pricing |
Go-to-market motion2 records
RedLeaf Biologics product offering
Product offeringCore offering
RedLeaf Biologics produces and sells ReDaxin™, a patented red sorghum leaf extract — a phenolic-rich (>20% polyphenols, including rare 3-deoxyanthocyanidins) botanical extract manufactured through a proprietary aqueous extraction process. The extract is sold as a formulation-ready bioactive raw ingredient to product manufacturers in the dietary supplement, functional food and beverage, and cosmetics industries, in multiple delivery formats including capsules/tablets, ready-to-drink beverages, powders and stick packs, gummies and gels, and cosmetic applications.
Product overview
RedLeaf Biologics offers a single flagship branded product — ReDaxin™ — rather than a multi-module platform. ReDaxin is the company's patented red sorghum leaf extract and is the central commercial offering around which all company messaging, R&D, clinical work, and certifications are organized. The extract is supplied as one core ingredient delivered across multiple application formats (capsules and tablets, ready-to-drink beverages, powders and stick packs, gummies and gels, functional foods, and cosmetic applications), rather than as a suite of distinct sub-products or modules. Supporting capabilities — including the proprietary non-GMO seed-to-extract U.S. value chain, plant-genetics and phytochemistry R&D, and clinical research in sports nutrition, cognition, and immune health — are positioned as enablers of the ReDaxin offering rather than as separately sold products.
Differentiator
Problem solved
Functional benefit
Brands
- ReDaxin: Patented red sorghum leaf extract; the first and only patented red sorghum leaf extract, a phenolic-rich botanical extract marketed for dietary supplement, functional food and beverage, and cosmetic applications.
Products and services
- ReDaxin™ ReDaxin™ is the first and only patented red sorghum leaf extract — a phenolic-rich botanical extract (>20% polyphenols, including luteolin, quercetin, hydroxycinnamic acids, and rare 3-deoxyanthocyanidins) produced via a proprietary aqueous extraction process. It is supplied as a formulation-ready bioactive raw ingredient for dietary supplement, functional food and beverage, and cosmetic applications, available in formats including capsules/tablets, ready-to-drink beverages, powders/stick packs, gummies/gels, functional foods, and cosmetic applications. Demonstrated functionality includes muscle strength recovery support, reduced muscle soreness, antioxidant activity, anti-inflammatory action, and immune modulation, with a University of Kentucky clinical study supporting the muscle strength recovery claim.
Companies that use RedLeaf Biologics
Customer profileIdeal customer profiles1 record
RedLeaf Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RedLeaf Biologics partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights5 records
RedLeaf Biologics competitors and assessment
Company assessmentBroad incumbents
- Kemin Industries: Global ingredient manufacturer supplying natural antioxidants, colorants, and antimicrobials to F&B, supplement, and pet/animal nutrition formulators. Comparable to RedLeaf as a botanical/bioactive ingredient supplier targeting the same B2B customer base, though Kemin operates a vastly larger, multi-ingredient portfolio.
- ADM (Archer Daniels Midland): Major agribusiness with a large Nutrition and Health Solutions segment supplying plant-based extracts, natural colors, and functional ingredients to F&B and supplement manufacturers. Directly comparable to RedLeaf on supply-side agronomy and ingredient-channel economics, with much greater scale.
- Givaudan (incl. Naturex): Through its Naturex acquisition, Givaudan is one of the largest suppliers of botanical extracts, natural colors, and fruit/vegetable-derived ingredients to F&B and nutraceutical formulators globally. Closest direct peer in the natural polyphenol/botanical extract category, but at incumbent scale.
- Chr. Hansen (now Novonesis): Global bioscience company supplying natural colors, antioxidants, and antimicrobial cultures to food and beverage manufacturers. Directly comparable on the natural colorant + antioxidant + antimicrobial function that RedLeaf is targeting, though at incumbent scale.
Direct peers
- Indena S.p.A. Italian botanical extract specialist supplying high-purity, clinically supported plant-derived active ingredients to dietary supplement, functional food, and cosmetic formulators. Directly comparable to RedLeaf on the botanical-ingredient-for-formulators model and clinical-evidence-led selling motion.
- Sabinsa: Supplier of patented, clinically-studied branded botanical extracts (e.g., Curcumin C3 Complex, BioPerine) to dietary supplement and functional food manufacturers. Highly comparable go-to-market: patented ingredient + clinical substantiation + B2B sales to formulators.
- OmniActive Health Technologies: Supplier of proprietary, science-backed botanical extracts (e.g., Lutemax, CurcuWin) to dietary supplement and functional food brands. Comparable branded-ingredient business model with clinical study support and a focus on differentiated polyphenol/carotenoid actives.
- AIDP Inc. U.S.-based distributor and developer of branded nutraceutical ingredients, including plant extracts, polyphenols, and functional food/beverage actives. Closely comparable in customer base (U.S. supplement and F&B formulators) and ingredient-platform approach.
- Blue California: Developer of clean-label, plant-based ingredients (e.g., Sondr Sleep, Relissa) sold to CPG and supplement brands. Comparable in positioning around proprietary, branded, natural actives marketed on clinical or mechanistic evidence.
- FutureCeuticals (by Microbiome Labs): Supplier of proprietary fruit-, vegetable-, and plant-derived ingredient powders and extracts to supplement, beverage, and functional food formulators, with clinical research support. Comparable in the proprietary-ingredient-for-formulators niche.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
RedLeaf Biologics social profiles
Digital presenceRedLeaf Biologics compliance and trust
Trust signalCompliance9 records
RedLeaf Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
RedLeaf Biologics leadership team
Management profileNumber of profiles
Profiles3 records
RedLeaf Biologics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RedLeaf Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RedLeaf Biologics
What does RedLeaf Biologics do?
RedLeaf Biologics produces and sells ReDaxin™, a patented red sorghum leaf extract — a phenolic-rich (>20% polyphenols, including rare 3-deoxyanthocyanidins) botanical extract manufactured through a proprietary aqueous extraction process. The extract is sold as a formulation-ready bioactive raw ingredient to product manufacturers in the dietary supplement, functional food and beverage, and cosmetics industries, in multiple delivery formats including capsules/tablets, ready-to-drink beverages, powders and stick packs, gummies and gels, and cosmetic applications.
Is RedLeaf Biologics a public or private company?
RedLeaf Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RedLeaf Biologics founded?
RedLeaf Biologics was founded in 2009. It employs 1 to 10 people.
Where is RedLeaf Biologics based?
RedLeaf Biologics is headquartered in Nicholasville, United States, in the North America region.
How does RedLeaf Biologics make money?
One revenue line is on record: B2B Ingredient Sales to Formulators.
Who are RedLeaf Biologics's main competitors?
Broad incumbents on record are Kemin Industries, ADM (Archer Daniels Midland), Givaudan (incl. Naturex) and Chr. Hansen (now Novonesis). Direct peers are Indena S.p.A., Sabinsa, OmniActive Health Technologies, AIDP Inc., Blue California and FutureCeuticals (by Microbiome Labs).
Does RedLeaf Biologics have an API?
No public API is recorded for RedLeaf Biologics.
What industry is RedLeaf Biologics in?
RedLeaf Biologics's product category is Botanical Extract Ingredients. Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts), with a secondary code of AFAJAKAI, Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol). Its NAICS code is 325411 and its SIC code is 2833.